- AU$4.04m
- AU$4.98m
- AU$0.38m
Brief: Invion Ltd Says Funding Agreements Cover Up To 85% Of Clinical Trials Costs
Brief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
Brief: Invion Signs First Ophthalmology Collaboration Agreement With Sangmyung Innovation
Brief: Invion Raises A$1.3 Million Through Convertible Note Offering
Brief: Invion Seeks Trading Halt
Brief: Invion Secures Non-Dilutive Funding From Hanlim Pharm And Korean Government Research Fund
Crescent Biopharma jumps after cancer drug partnership
Brief: Invion Secures Exclusive Perpetual Global Rights For Photosoft
Australia's Invion gains on new medical technology license
Brief: Invion Ltd Seeks Trading Halt Pending Capital Raising Announcement
Brief: Invion Ltd Post FY Loss Attributable A$8.8 Million
Brief: Invion Says Orphan Drug Designation Granted By U.S. FDA For Anal Cancer
Brief: Invion Seeks Trading Halt
Australia's Invion drops to 1-week low on termination of share purchase agreement
Brief: Invion Ltd Seeks Trading Halt
Brief: Invion Expands Agreement With Hanlim To Include Oesophageal Cancer
Australia's Invion jumps most in 3 yrs as skin cancer treatment trial begins
Brief: Invion Ltd Announces Agreement With Major South Korean Pharma Group Hanlim